You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

niLOtinib

( ne-LOE-ti-nib )
Funding:
Exceptional Access Program
  • niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
  • niLOtinib - Chronic phase Ph+ CML, with specific criteria
Other Name(s): Tasigna®
Appearance: capsule in various strengths and colours

You might also be interested in